A Professional Service Provider for the Pharma Industry
In a recent blog we took issue with a Nature article about ‘Lessons learned’ after a TIGIT inhibitor failed in late Phase 3 development. We felt that the article provided few insights, mainly platitudes. This week we saw a different kind of post-mortem. It was about VRG50635, a PIKfyve inhibitor Continue reading VRG50635 – Lessons Learned in ALS
In 1886, Weil published detailed case descriptions of 4 patients with icterus, splenic enlargement and nephritis [1]. All four patients presented with acute onset of fever, elevated liver function tests (LFTs), hepatic enlargement, splenomegaly, and proteinuria. Two cases were recorded more than12 years earlier, but the author felt that they Continue reading On Leptospirosis (Weil’s Disease)
There was not much for us to report on this summer that would interest our readership… Let’s skip the Fauci / Paul senate drama regarding the origins of Covid, with senator Paul taking the role of the Grand Inquisitor and Dr. Fauci the Fifth. The latest act in this screen Continue reading Avacopan / TAVNEOS Follow-Up